- Home
- CGO vs SRTS Comparison
CGO vs SRTS Comparison
Compare CGO & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- SRTS
- Stock Information
- Founded
- CGO 2004
- SRTS 2010
- Country
- CGO United States
- SRTS United States
- Employees
- CGO N/A
- SRTS N/A
- Industry
- CGO Investment Managers
- SRTS Medical/Dental Instruments
- Sector
- CGO Finance
- SRTS Health Care
- Exchange
- CGO Nasdaq
- SRTS Nasdaq
- Market Cap
- CGO 111.7M
- SRTS 110.3M
- IPO Year
- CGO N/A
- SRTS 2016
- Fundamental
- Price
- CGO $11.26
- SRTS $6.56
- Analyst Decision
- CGO
- SRTS Strong Buy
- Analyst Count
- CGO 0
- SRTS 2
- Target Price
- CGO N/A
- SRTS $12.50
- AVG Volume (30 Days)
- CGO 34.7K
- SRTS 240.1K
- Earning Date
- CGO 01-01-0001
- SRTS 02-06-2025
- Dividend Yield
- CGO 9.25%
- SRTS N/A
- EPS Growth
- CGO N/A
- SRTS N/A
- EPS
- CGO N/A
- SRTS 0.57
- Revenue
- CGO N/A
- SRTS $41,308,000.00
- Revenue This Year
- CGO N/A
- SRTS $65.04
- Revenue Next Year
- CGO N/A
- SRTS $24.87
- P/E Ratio
- CGO N/A
- SRTS $11.53
- Revenue Growth
- CGO N/A
- SRTS 65.62
- 52 Week Low
- CGO $7.90
- SRTS $2.61
- 52 Week High
- CGO $10.93
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- CGO 40.46
- SRTS 37.12
- Support Level
- CGO $11.10
- SRTS $6.38
- Resistance Level
- CGO $11.23
- SRTS $6.93
- Average True Range (ATR)
- CGO 0.23
- SRTS 0.40
- MACD
- CGO -0.02
- SRTS -0.03
- Stochastic Oscillator
- CGO 47.41
- SRTS 13.64
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in global equities, convertible securities, and high-yield corporate bonds.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.